Cogent Biosciences, Inc. COGT Accrued Expenses And Other Liabilities Current
Accrued Expenses And Other Liabilities Current at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept cogt:AccruedExpensesAndOtherLiabilitiesCurrent.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s accrued expenses and other liabilities current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s accrued expenses and other liabilities current?
- Cogent Biosciences, Inc. (COGT) reported accrued expenses and other liabilities current of $42.85M in Q1 2026.
- How has Cogent Biosciences, Inc.'s accrued expenses and other liabilities current changed year-over-year?
- Cogent Biosciences, Inc.'s accrued expenses and other liabilities current increased by 27.7% year-over-year, from $33.55M to $42.85M.
- What is the long-term trend for Cogent Biosciences, Inc.'s accrued expenses and other liabilities current?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s accrued expenses and other liabilities current has grown at a 61.7% compound annual growth rate (CAGR), from $4.78M to $52.9M.
- What does accrued expenses and other liabilities current mean?
- This represents the aggregate of short-term obligations that have been incurred but not yet invoiced or paid, such as accrued compensation, professional fees, or clinical trial costs. It serves as a key indicator of near-term operational cash outflows required to settle ongoing business activities. Monitoring this balance helps investors assess the company's short-term liquidity position and the timing of upcoming cash requirements.